1.

Longitudinal study based on a safety registry for malaria patients treated with artenimol-piperaquine in six European countries.

2.

Longitudinal study based on a safety registry for malaria patients treated with artenimol-piperaquine in six European countries.

1.

Antibodies against carbamylated proteins: prevalence and associated disease characteristics in Belgian patients with rheumatoid arthritis or other rheumatic diseases.

2.

Antibodies against carbamylated proteins: prevalence and associated disease characteristics in Belgian patients with rheumatoid arthritis or other rheumatic diseases.

3.

Antibodies against carbamylated proteins: prevalence and associated disease characteristics in Belgian patients with rheumatoid arthritis or other rheumatic diseases.

4.

Antibodies against carbamylated proteins: prevalence and associated disease characteristics in Belgian patients with rheumatoid arthritis or other rheumatic diseases.

5.

Antibodies against carbamylated proteins: prevalence and associated disease characteristics in Belgian patients with rheumatoid arthritis or other rheumatic diseases.

6.

Antibodies against carbamylated proteins: prevalence and associated disease characteristics in Belgian patients with rheumatoid arthritis or other rheumatic diseases.

7.

Antibodies against carbamylated proteins: prevalence and associated disease characteristics in Belgian patients with rheumatoid arthritis or other rheumatic diseases.

8.

Antibodies against carbamylated proteins: prevalence and associated disease characteristics in Belgian patients with rheumatoid arthritis or other rheumatic diseases.

9.

Antibodies against carbamylated proteins: prevalence and associated disease characteristics in Belgian patients with rheumatoid arthritis or other rheumatic diseases.

1.

Long-term changes in the perception of Job Characteristics

2.

Long-term changes in the perception of Job Characteristics

1.

Emotional Fit With Culture: A Predictor of Individual Differences in Relational Well-Being

2.

Emotional Fit With Culture: A Predictor of Individual Differences in Relational Well-Being

1.

Exploring the discrimination–radicalization nexus: empirical evidence from youth and young adults in Belgium

2.

Exploring the discrimination–radicalization nexus: empirical evidence from youth and young adults in Belgium

3.

Exploring the discrimination–radicalization nexus: empirical evidence from youth and young adults in Belgium

4.

Exploring the discrimination–radicalization nexus: empirical evidence from youth and young adults in Belgium

5.

Exploring the discrimination–radicalization nexus: empirical evidence from youth and young adults in Belgium

6.

Exploring the discrimination–radicalization nexus: empirical evidence from youth and young adults in Belgium

7.

Exploring the discrimination–radicalization nexus: empirical evidence from youth and young adults in Belgium

8.

Exploring the discrimination–radicalization nexus: empirical evidence from youth and young adults in Belgium

9.

Exploring the discrimination–radicalization nexus: empirical evidence from youth and young adults in Belgium

1.

Treatment needs and impact of oral health screening of athletes with intellectual disability in Belgium

2.

Treatment needs and impact of oral health screening of athletes with intellectual disability in Belgium

3.

Treatment needs and impact of oral health screening of athletes with intellectual disability in Belgium

4.

Treatment needs and impact of oral health screening of athletes with intellectual disability in Belgium

5.

Treatment needs and impact of oral health screening of athletes with intellectual disability in Belgium

1.

Survey of Pseudomonas aeruginosa genotypes in colonised cystic fibrosis patients

2.

Survey of Pseudomonas aeruginosa genotypes in colonised cystic fibrosis patients

3.

Survey of Pseudomonas aeruginosa genotypes in colonised cystic fibrosis patients

4.

Survey of Pseudomonas aeruginosa genotypes in colonised cystic fibrosis patients

5.

Survey of Pseudomonas aeruginosa genotypes in colonised cystic fibrosis patients

1.

Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumab.

2.

Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumab.

3.

Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumab.

4.

Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumab.

5.

Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumab.

6.

Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumab.

7.

Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumab.

8.

Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumab.

1.

The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer...

2.

The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer...

3.

The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer...

4.

The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer...

5.

The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer...

1.

Processing Phage Therapy Requests in a Brussels Military Hospital: Lessons Identified.

2.

Processing Phage Therapy Requests in a Brussels Military Hospital: Lessons Identified.